Business ❯Pharmaceuticals ❯Acquisitions ❯Private Equity
Sanofi's decision to sell 50% of its Doliprane-producing subsidiary to an American fund has sparked political uproar and worker strikes, prompting state investment and negotiations to secure jobs and production in France.
